Navigation Links
Lutonix Inc. Announces $20 Million Series B Financing
Date:10/27/2008

Versant Ventures Leads Investment in Lutonix to Fund Human Clinical Trials

MINNEAPOLIS, Oct. 27 /PRNewswire/ -- Lutonix Inc., today announced the close of a $20 million Series B financing. Co-Founded in July 2007 by Dennis Wahr, M.D. and Lixiao Wang PhD, Lutonix is a medical device company focused on the development and commercialization of drug coated balloon angioplasty technology for the treatment and prevention of coronary and peripheral artery stenosis caused by atherosclerosis. Lutonix's drug coated balloon technology is anticipated to enhance therapeutic options for patients who are candidates for conventional therapies such as balloon angioplasty and stents and for those who are no longer likely to benefit from those treatments. Lutonix's first targeted indication is expected to be the treatment and prevention of vascular restenosis through the use of its proprietary, drug coated balloon angioplasty catheter. Lutonix will use the new capital for continued product development activities and to fund the company's initial human clinical trials.

The round was led by Versant Ventures (http://www.versantventures.com), a leading healthcare-focused venture capital firm, that was joined by new investor, Delphi Ventures (http://www.Delphiventures.com). Also participating in this round were both Series A investors, U.S. Venture Partners (http://www.usvp.com) and founding venture firm RiverVest Venture Partners (http://www.rivervest.com). In conjunction with the financing, Kevin Wasserstein, Managing Director of Versant Ventures, and John Maroney, Managing Director of Delphi Ventures have been added to the Board of Directors, which also includes: Jonathan Root, M.D., Managing Director of U.S. Venture Partners; Jay Schmelter, Managing Dire
'/>"/>

SOURCE Lutonix Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... WASHINGTON , May 22, 2015  The ... certain diagnosed victims of mesothelioma get the best ... making certain individuals with this rare cancer caused ... the most up-to-date information related to treatment options ... information please call the Mesothelioma Victims Center anytime ...
(Date:5/22/2015)... Today, Rhodes Pharmaceuticals L.P. announced that Aptensio ... for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) will ... The announcement comes just one month ... Food and Drug Administration (FDA). ... capsule with an onset of effect of 1 ...
(Date:5/21/2015)... DUBLIN , May 21, 2015 /PRNewswire/ ... http://www.researchandmarkets.com/research/5x377m/north_american ) has announced the addition of ... by Type (Ankle Replacement, Digit Replacement, Elbow ... - Forecast to 2019" report to ... market for knee replacement was valued at ...
Breaking Medicine Technology:Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 2Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 3Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 4Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 5Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 2Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 5Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 6North American Joint Reconstruction Market 2015-2019 - Zimmer Holdings, DePuy Synthes Companies, Stryker, Biomet & Smith & Nephew Dominates the $4.4 Billion Market 2
... in a physicians office practice, can be instrumental ... ailments; UTIs, diabetes, several cancers, metabolic disorders, cardiovascular ... for urinalysis tests is well in excess of ... For such a fundamental, extensive and economically significant ...
... large multi-site lab faced challenges with manual document ... were exacerbated by staff shortages and growing test ... was essential for accreditation compliance and also to ... manage documents. They therefore assessed a variety of ...
Cached Medicine Technology:Urinalysis Analyzers: Large Capabilities in Every Size Device 2Urinalysis Analyzers: Large Capabilities in Every Size Device 3Choosing Lab Quality Management Software 2Choosing Lab Quality Management Software 3Choosing Lab Quality Management Software 4
(Date:5/24/2015)... Pacific Prime has announced that they have launched the second ... of individual international health insurance. Titled: The Cost of Health Insurance ... health insurance in six top expat destinations, which are also popular ... Kong , Singapore , China , ... UK , Article 2 presents an in-depth look at ...
(Date:5/24/2015)... Scientists with Cardno ChemRisk, a scientific ... compliance issues that may have raised the risk of ... just posted an article on the research. Click ... found airborne asbestos levels well above OSHA safety guidelines ... 2011. , “Asbestos compliance sampling data associated with the ...
(Date:5/24/2015)... Medicx Media Solutions http://www.medicxmedia.com ... Jay Krihak as its head of programmatic strategy ... its expertise and leadership position in the data ... sectors. , Krihak is an experienced, award-winning agency ... led sales planning teams for mobile platform Jumptap. ...
(Date:5/23/2015)... 2015 Dr. David Benvenuti, an experienced plastic ... a new article to his website that takes ... Benvenuti explained in the fascinating blog, he has recently ... earlobes. , Known as “gauging,” the technique involves placing larger ... Benvenuti said will eventually stretch the holes out to incredible ...
(Date:5/23/2015)... 23, 2015 A live auction will be ... hospitals, surgery centers and other medical facilities around the United ... endoscopy, lab, radiology, surgery, anesthesia, exam and much more. ... and Thursday, May 28 starting at 9:00am CDT each day. ... N. 25th Avenue, Melrose Park, IL 60160. Anyone can ...
Breaking Medicine News(10 mins):Health News:Pacific Prime Releases 2nd Article of Cost of Health Insurance Report 2Health News:New Analysis Finds Too Many Employers Ignored OSHA Asbestos Guidelines, According to Surviving Mesothelioma 2Health News:Medicx Media Solutions Expands Executive Team 2Health News:Dr. Benvenuti, a Plastic Surgeon in Newport Beach, CA, Posts New Article about Repairing Ear Gauges 2Health News:Over 5,200 Lots of Medical Equipment Will Be Sold by Live Auction 2
... Amgen (Nasdaq: AMGN ) will present ... on Monday, May 18, 2009 at the InterContinental, Boston, ... and Chief Executive Officer Kevin Sharer will present. Live ... Internet and can be accessed from Amgen,s Web site, ...
... treatment prolonged survival in older women, study finds , ... with early-stage breast cancer do better after standard chemotherapy ... a new study finds. , "After three years, 85 ... and 68 percent of people who received capecitabine ...
... ("SCA") today announced that it will host an investor ... May 19, 2009, to discuss its 2009 first quarter ... ) Please go to SCA,s Intralinks website to obtain ... or contact Kathleen Vojta at 205-545-2693 or by e-mail ...
... Inc. ("Transition" or the "Company") (TSX: TTH; NASDAQ: ... for disease indications with large markets, today announced its ... Selected Highlights, -------------------, ... 2009 and up to the date of this press,release, ...
... VIEW, Calif., May 13 MAP Pharmaceuticals, Inc. (Nasdaq: ... at the Deutsche Bank Securities 34th Annual Health ... (ET) in Boston, MA.A live webcast of the presentation will ... website at http://www.mappharma.com . A replay will also be ...
... Katherine Borden, at the Institute for Research in Immunology ... shown that a common anti-viral drug, ribavirin, can be ... the journal Blood (First Edition), the study ... gene in patients. This gene is dysregulated in 30 ...
Cached Medicine News:Health News:Chemotherapy Superior to New Drug for Early Breast Cancer 2Health News:Chemotherapy Superior to New Drug for Early Breast Cancer 3Health News:Transition Therapeutics Announces Third Quarter Fiscal 2009 Financial Results 2Health News:Transition Therapeutics Announces Third Quarter Fiscal 2009 Financial Results 3Health News:Transition Therapeutics Announces Third Quarter Fiscal 2009 Financial Results 4Health News:Transition Therapeutics Announces Third Quarter Fiscal 2009 Financial Results 5Health News:Transition Therapeutics Announces Third Quarter Fiscal 2009 Financial Results 6Health News:Transition Therapeutics Announces Third Quarter Fiscal 2009 Financial Results 7Health News:Transition Therapeutics Announces Third Quarter Fiscal 2009 Financial Results 8Health News:Transition Therapeutics Announces Third Quarter Fiscal 2009 Financial Results 9Health News:Transition Therapeutics Announces Third Quarter Fiscal 2009 Financial Results 10Health News:Novel therapy may prove effective in treatment of 30 percent of cancers 2
Smooth, round edges allow for safe manipulation within the eye. 1.1mm wide gradually tapers to .50 mm wide. 45, 1.1mm wide, gradually tapers to .50mm wide....
Designed to lift corneal cap/flap during corneal lamellar surgery...
Pre-expanded for convenience; no need to pre-soak and fan. Lint-free PVAmaterial...
Angled 45, 9mm from end, Longer design from bend to tip allows for easier placement of viscoelastic to all meridians, Dome shape, extra smooth tip...
Medicine Products: